Methylphenidate HCl: therapy for attention deficit hyperactivity disorder

  title={Methylphenidate HCl: therapy for attention deficit hyperactivity disorder},
  author={Philip K Capp and Phillip L. Pearl and Charles Conlon},
  journal={Expert Review of Neurotherapeutics},
  pages={325 - 331}
Methylphenidate is a first-line therapy for attention deficit hyperactivity disorder, the most prevalent neuropsychiatric disorder of childhood. The compound is a piperidine and the D-threo-isomer is considered the biologically active form. The compound is available in multiple short- and long-acting preparations, having different delivery systems leading to varying kinetics without clear superiority in efficacy or tolerability at the group level. Common adverse effects are insomnia, appetite… 

Methylphenidate-induced psychosis in a young antipsychotic-naïve female patient

A case report of MPD-induced psychosis in a 31-year-old, antipsychotic-naïve patient is presented and careful evaluation is recommended each time MPD treatment is initiated.

Effects of Once-Daily Oral and Transdermal Methylphenidate on Sleep Behavior of Children With ADHD

Little evidence is found that methylphenidate treatment (at least in sustained-release forms) was a significant cause of sleep problems in treated children who were carefully titrated to an optimal dose.

Metabolomics of Methylphenidate and Ethylphenidate: Implications in Pharmacological and Toxicological Effects

  • R. Dinis-Oliveira
  • Biology, Chemistry
    European Journal of Drug Metabolism and Pharmacokinetics
  • 2016
It is expected that knowing the metabolomics of MPH may provide further insights regarding individual contribution for MPH pharmacodynamics and toxicological effects, namely if ethanol is co-consumed.

Methylphenidate Exposure Induces Dopamine Neuron Loss and Activation of Microglia in the Basal Ganglia of Mice

It is suggested that chronic MPH usage in mice at doses spanning the therapeutic range in humans, especially at prolonged higher doses, has long-term neurodegenerative consequences.

Methylphenidate Enhances NMDA-Receptor Response in Medial Prefrontal Cortex via Sigma-1 Receptor: A Novel Mechanism for Methylphenidate Action

It is demonstrated for the first time that MPH facilitates NMDA-receptor mediated synaptic transmission via σ1 receptor, and such facilitation requires PLC/IP3/PKC signaling pathway, which possibly explains the underlying mechanism for MPH induced addictive potential and other psychiatric side effects.

Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy.

Analysis of tic episodes per patient in this study found no correlation between an OROS MPH dose and the frequency of tics, suggesting that MPH-based therapy does not significantly induce or exacerbate tics in children with ADHD.

A Review of the Pathophysiology, Etiology, and Treatment of Attention-Deficit Hyperactivity Disorder (ADHD)

This review focuses on the pathophysiology, etiology, and treatment of ADHD and details the adverse effects and drug interaction profiles of the drugs used to treat it.

Effect of Methylphenidate on Sleep Parameters in Children with ADHD

Investigation of the acute impact of methylphenidate on sleep parameters in attention-deficit/hyperactivity disorder (ADHD) children found MPH had negative impacts on sleep among young ADHD children, but different preparations and doses did not affect the result.



Advances in the Pharmacotherapy of Attention‐Deficit‐Hyperactivity Disorder: Focus on Methylphenidate Formulations

The psychostimulant dl‐methylphenidate (MPH) remains the most common drug therapy in child and adolescent psychiatry for the treatment of attention‐deficit‐hyperactivity disorder (ADHD). Evidence of

Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation.

Stimulant medication within this therapeutic range, therefore, results in few, generally mild side effects, and Surprisingly, a high frequency of these behavior side effects were reported during the placebo condition.

Use of methylphenidate in a patient with glaucoma and attention-deficit hyperactivity disorder: a clinical dilemma.

When used cautiously in conjunction with glaucoma medications and regular ophthalmologic monitoring, methylphenidate and other psychostimulants may be safe in patients with well-controlled, open-angle glau coma.

Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial.

Many symptoms commonly attributed to stimulant medication are actually preexisting characteristics of children with ADHD and improve with stimulant treatment.

Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder

Atomoxetine (Strattera™, Eli Lilly & Co.) is a selective noradrenaline reuptake inhibitor that has been studied for use in the treatment of attention-deficit/hyperactivity disorder (ADHD). So far,

Use of Methylphenidate for Attention-Deficit Hyperactivity Disorder in Patients With Epilepsy or Electroencephalographic Abnormalities

Methylphenidate is safe and effective in children with ADHD and concomitant active seizures or EEG abnormalities and had a beneficial effect on EEG.

Serum and brain concentrations of methylphenidate: implications for use and abuse

The acute effect of methylphenidate on cerebral blood flow in boys with attention-deficit/hyperactivity disorder

The findings suggest that the posterior attentional system, which includes the parietal cortex, may have a role in the mediation of the therapeutic effects of MPH in ADHD.